Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.34 |
| ▸ | MMP9 | P14780 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17694560 | 0.87 | — | — | |
| SCHEMBL17694552 | 0.85 | RARB (0.36) | MAPTKDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL536401 | 0.82 | MMP2 (0.46) | MMP2MMP9PDK2MMP8MMP13 | |
| SCHEMBL28942264 | 0.82 | MMP2 (0.46) | MMP2MMP9PDK2MMP8MMP13 | |
| SCHEMBL12222874 | 0.80 | PDK2 (0.35) | MMP2MMP9MAPTPDK2MMP8 | |
| SCHEMBL17676869 | 0.80 | — | — | |
| SCHEMBL17108443 | 0.79 | PDK2 (0.40) | MMP2MMP9PDK2MMP8MMP13 | |
| SCHEMBL25444664 | 0.79 | PDK2 (0.33) | MMP2MMP9PDK2MMP8MMP13 | |
| SCHEMBL17118404 | 0.79 | PDK2 (0.38) | MMP2MMP9PDK2MMP8MMP13 | |
| SCHEMBL10019514 | 0.78 | MMP2 (0.37) | MMP2MMP9PDK2MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777026-B2 | Branched oligoarylsilanes and method for producing same | LUMINESCENT INNOVATION TECHNOLOGIES LLC (RU) | 2017-10-03 | — | — | US | disclosed |
| US-20160108065-A1 | Branched Oligoarylsilanes and Method for Producing Same | LUMINESCENT INNOVATION TECHNOLOGIES LLC (RU) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108065-A1 | Branched Oligoarylsilanes and Method for Producing Same | SIK3, SIK2, SIK1 | MMP2 2841/4885MMP9 3211/4885MAPT 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.